Mineralys Therapeutics (NASDAQ: MLYS) announced that its management will participate in the Jefferies 2026 Global Healthcare Conference in New York from June 2-4, 2026.
The company is scheduled for a corporate presentation on June 3, 2026 at 7:35 a.m. EDT, with a live webcast available via its Investor Relations “News & Events” page.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MLYS
+0.07%
+0.07%Session close to close
In the May 27 session, MLYS gained 0.07%, reflecting a mild positive market reaction.
This announcement highlights Mineralys’ upcoming corporate presentation at a major healthcare confer...
Analysis
This announcement highlights Mineralys’ upcoming corporate presentation at a major healthcare conference, offering additional visibility into its hypertension-focused pipeline. In recent months, the company has reported FDA acceptance of its NDA for lorundrostat and presented late-stage clinical data, indicating an advanced development stage. Investors may watch how management’s messaging at the conference reinforces these milestones, alongside ongoing regulatory filings and insider trading activity, as they assess execution and potential future developments.
Scheduling of Q1 2026 results release and accompanying conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive regulatory and clinical updates often saw negative or muted next-day price reactions, while routine scheduling news has produced mixed but sometimes positive moves.
Recent Company History
Over the last few months, Mineralys has reported several key milestones. On May 6, 2026, it announced Q1 results and FDA acceptance of the NDA for lorundrostat, yet shares fell despite this positive regulatory step. A May 18, 2026 Phase 3 Launch-HTN data presentation was similarly followed by a modest decline. By contrast, routine items like inducement awards and earnings-date or conference announcements produced mixed but sometimes positive reactions, suggesting limited immediate trading impact from schedule-focused news like today’s conference participation.
Key Terms
chronic kidney disease, ckd, obstructive sleep apnea, osa, +2 more
6 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea..."
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
ckdmedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea..."
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
obstructive sleep apneamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)..."
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
osamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)..."
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
aldosteronemedical
"other diseases driven by dysregulated aldosterone, today announced that management..."
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
hypertensionmedical
"developing medicines to target hypertension and related comorbidities such as..."
Hypertension is a condition where blood pressure in the arteries remains consistently high, making the heart work harder than normal to pump blood through the body. For investors, it can signal underlying health issues that might lead to increased medical costs or decreased productivity, potentially affecting a company's stability or the overall economy. Think of it as a warning sign of ongoing strain within a system that needs careful monitoring.
RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Jefferies 2026 Global Healthcare Conference being held in New York on June 2-4, 2026.
A live webcast of this presentation can also be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
When will Mineralys Therapeutics (NASDAQ: MLYS) present at the Jefferies 2026 Global Healthcare Conference?
Mineralys Therapeutics is scheduled to present on Wednesday, June 3, 2026 at 7:35 a.m. EDT. According to the company, this session is part of the Jefferies 2026 Global Healthcare Conference in New York.
What type of session will Mineralys Therapeutics (MLYS) hold at the Jefferies 2026 conference?
Mineralys Therapeutics will deliver a corporate presentation at the Jefferies 2026 Global Healthcare Conference. According to the company, this presentation provides an overview of its hypertension-focused biopharmaceutical programs.
How can investors access the Mineralys Therapeutics (MLYS) webcast from the Jefferies 2026 Global Healthcare Conference?
Investors can access a live webcast of the Mineralys presentation via the company’s Investor Relations website. According to Mineralys, it will be available on the “News & Events” page for online viewing.
Where is the Jefferies 2026 Global Healthcare Conference featuring Mineralys Therapeutics (MLYS) being held?
The Jefferies 2026 Global Healthcare Conference featuring Mineralys Therapeutics is being held in New York. According to the company, its management presentation is scheduled there on June 3, 2026.
What does Mineralys Therapeutics focus on, as highlighted in its Jefferies 2026 conference participation?
Mineralys Therapeutics focuses on developing medicines targeting hypertension and related comorbidities. According to the company, these include chronic kidney disease, obstructive sleep apnea, and other conditions driven by dysregulated aldosterone.
